Journal
TOWARD PERSONALIZED MEDICINE FOR CANCER
Volume 1210, Issue -, Pages 86-93Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2010.05777.x
Keywords
breast cancer; fatty acid synthase (FASN); novel anti-FASN compounds; HER2; preclinical study
Ask authors/readers for more resources
Fatty acid synthase (FASN) expression and activity has emerged as a common phenotype in most human carcinomas, including breast cancer, and its expression is tightly linked to HER2 signaling pathways. The development of inhibitors of FASN activity has consequently appeared as a novel antitarget modality for treating cancer. However, the clinical use of FASN inhibitors, such as cerulenin, C75, and epigallocatechin 3-gallate (EGCG), is limited by anorexia and induced body weight loss or by its low in vivo potency and stability. Here, we summarize the design and development of G28UCM, the lead-compound of a novel family of synthetic FASN inhibitors, with both in vitro and in vivo activity in a human breast cancer model of FASN(+) and HER2(+).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available